{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T09:15:08Z","timestamp":1793697308488,"version":"4.5.1"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2023,8,3]],"date-time":"2023-08-03T00:00:00Z","timestamp":1691020800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,8,3]],"date-time":"2023-08-03T00:00:00Z","timestamp":1691020800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001407","name":"Department of Biotechnology, Ministry of Science and Technology, India","doi-asserted-by":"publisher","award":["BT\/PR23283\/MED\/30\/1953\/2018"],"award-info":[{"award-number":["BT\/PR23283\/MED\/30\/1953\/2018"]}],"id":[{"id":"10.13039\/501100001407","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Invest New Drugs"],"published-print":{"date-parts":[[2023,10]]},"DOI":"10.1007\/s10637-023-01387-y","type":"journal-article","created":{"date-parts":[[2023,8,2]],"date-time":"2023-08-02T23:21:41Z","timestamp":1691018501000},"page":"652-663","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Development and characterization of fused human arginase I for cancer therapy"],"prefix":"10.1007","volume":"41","author":[{"given":"Snehal Sainath","family":"Jawalekar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priyanka Sugriv","family":"Kawathe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nisha","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J","family":"Anakha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kulbhushan","family":"Tikoo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abhay H.","family":"Pande","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,8,3]]},"reference":[{"issue":"3","key":"1387_CR1","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1016\/j.cell.2016.09.031","volume":"167","author":"R Geiger","year":"2016","unstructured":"Geiger R, Rieckmann JC, Wolf T, Basso C, Feng Y, Fuhrer T, Kogadeeva M, Picotti P, Meissner F, Mann M, Zamboni N (2016) L-arginine modulates T cell metabolism and enhances survival and anti-tumor activity. Cell\u00a0167(3):829\u2013842","journal-title":"Cell"},{"issue":"10","key":"1387_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s13205-022-03326-9","volume":"12","author":"J Anakha","year":"2022","unstructured":"Anakha J, Kawathe PS, Datta S, Jawalekar SS, Banerjee UC, Pande AH (2022) Human arginase 1, a Jack of all trades? 3 Biotech 12(10):1\u20139","journal-title":"3 Biotech"},{"issue":"11","key":"1387_CR3","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.2174\/138161208784246199","volume":"14","author":"L Feun","year":"2008","unstructured":"Feun L, You M, Wu CJ, Kuo MT, Wangpaichitr M, Spector S, Savaraj N (2008) Arginine deprivation as a targeted therapy for cancer. Curr Pharm Design 14(11):1049\u20131057","journal-title":"Curr Pharm Design"},{"issue":"12","key":"1387_CR4","doi-asserted-by":"crossref","first-page":"2762","DOI":"10.1002\/ijc.25202","volume":"126","author":"B Delage","year":"2010","unstructured":"Delage B, Fennell DA, Nicholson L, McNeish I, Lemoine NR, Crook T, Szlosarek PW (2010) Arginine deprivation and argininosuccinate synthetase expression in the treatment of cancer. Int J Cancer 126(12):2762\u20132772","journal-title":"Int J Cancer"},{"issue":"7","key":"1387_CR5","doi-asserted-by":"publisher","first-page":"e342","DOI":"10.1038\/cddis.2012.83","volume":"3","author":"B Delage","year":"2012","unstructured":"Delage B, Luong P, Maharaj L, O\u2019riain C, Syed N, Crook T, Hatzimichael E, Papoudou-Bai A, Mitchell TJ, Whittaker SJ, Cerio R (2012) Promoter methylation of argininosuccinate synthetase-1 sensitises lymphomas to arginine deiminase treatment, autophagy and caspase-dependent apoptosis. Cell Death Dis 3(7):e342\u2013e342","journal-title":"Cell Death Dis"},{"issue":"41","key":"1387_CR6","doi-asserted-by":"publisher","first-page":"67223","DOI":"10.18632\/oncotarget.11615","volume":"7","author":"H Jeon","year":"2016","unstructured":"Jeon H, Kim JH, Lee E, Jang YJ, Son JE, Kwon JY, Lim TG, Kim S, Park JH, Kim JE, Lee KW (2016) Methionine deprivation suppresses triple-negative breast cancer metastasis in vitro and in vivo. Oncotarget 7(41):67223-67234","journal-title":"Oncotarget"},{"key":"1387_CR7","doi-asserted-by":"publisher","first-page":"582587","DOI":"10.3389\/fphar.2020.582587","volume":"11","author":"Z Wang","year":"2021","unstructured":"Wang Z, Xie Q, Zhou H, Zhang M, Shen J, Ju D (2021) Amino acid degrading enzymes and autophagy in cancer therapy. Front Pharmacol 11:582587","journal-title":"Front Pharmacol"},{"issue":"3","key":"1387_CR8","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1021\/cb900267j","volume":"5","author":"EM Stone","year":"2010","unstructured":"Stone EM, Glazer ES, Chantranupong L, Cherukuri P, Breece RM, Tierney DL, Curley SA, Iverson BL, Georgiou G (2010) Replacing Mn2+ with Co2+ in human arginase I enhances cytotoxicity toward L-arginine auxotrophic cancer cell lines. ACS Chem Biol 5(3):333\u2013342","journal-title":"ACS Chem Biol"},{"issue":"1","key":"1387_CR9","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1158\/0008-5472.CAN-06-1945","volume":"67","author":"PN Cheng","year":"2007","unstructured":"Cheng PN, Lam TL, Lam WM, Tsui SM, Cheng AW, Lo WH, Leung YC (2007) Pegylated recombinant human arginase (rhArg-peg5, 000mw) inhibits the in vitro and in vivo proliferation of human hepatocellular carcinoma through arginine depletion. Cancer Res 67(1):309\u2013317","journal-title":"Cancer Res"},{"issue":"2","key":"1387_CR10","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1111\/j.1755-148X.2010.00798.x","volume":"24","author":"TL Lam","year":"2011","unstructured":"Lam TL, Wong GK, Chow HY, Chong HC, Chow TL, Kwok SY, Cheng PN, Wheatley DN, Lo WH, Leung YC (2011) Recombinant human arginase inhibits the in vitro and in vivo proliferation of human melanoma by inducing cell cycle arrest and apoptosis. Pigment cell melanoma res 24(2):366\u2013376","journal-title":"Pigment cell melanoma res"},{"issue":"38","key":"1387_CR11","doi-asserted-by":"publisher","first-page":"4957","DOI":"10.1038\/onc.2016.37","volume":"35","author":"MD Patil","year":"2016","unstructured":"Patil MD, Bhaumik J, Babykutty S, Banerjee UC, Fukumura D (2016) Arginine dependence of tumor cells: targeting a chink in cancer\u2019s armor. Oncogene 35(38):4957\u20134972","journal-title":"Oncogene"},{"issue":"3","key":"1387_CR12","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1593\/tlo.10265","volume":"4","author":"ES Glazer","year":"2011","unstructured":"Glazer ES, Stone EM, Zhu C, Massey KL, Hamir AN, Curley SA (2011) Bioengineered human arginase I with enhanced activity and stability controls hepatocellular and pancreatic carcinoma xenografts. Translational Oncol 4(3):138\u2013146","journal-title":"Translational Oncol"},{"issue":"9","key":"1387_CR13","doi-asserted-by":"publisher","first-page":"3921","DOI":"10.1007\/s00253-020-10484-4","volume":"104","author":"SF Chung","year":"2020","unstructured":"Chung SF, Kim CF, Tam SY, Choi MC, So PK, Wong KY, Leung YC, Lo WH (2020) A bioengineered arginine-depleting enzyme as a long-lasting therapeutic agent against cancer. Appl Microbiol Biotechnol 104(9):3921\u20133934","journal-title":"Appl Microbiol Biotechnol"},{"issue":"3","key":"1387_CR14","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1677\/JOE-09-0211","volume":"203","author":"JF Langenheim","year":"2009","unstructured":"Langenheim JF, Chen WY (2009) Improving the pharmacokinetics\/pharmacodynamics of prolactin, GH, and their antagonists by fusion to a synthetic albumin-binding peptide. J Endocrinol 203(3):375","journal-title":"J Endocrinol"},{"key":"1387_CR15","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1002\/9780470939932.ch14","volume":"54","author":"CJ Fee","year":"2011","unstructured":"Fee CJ, Van Alstine JM (2011) Purification of pegylated proteins.\u00a0 Methods Biochem Anal 54,\u00a0339\u2013362","journal-title":"Protein Purification: Principles High Resolution Methods and Applications"},{"key":"1387_CR16","doi-asserted-by":"crossref","unstructured":"Li L, Wang Y, Chen J, Cheng B, Hu J, Zhou Y, Gao X, Gao L, Mei X, Sun M, Zhang Z (2013) An engineered arginase FC protein inhibits tumor growth in vitro and in vivo. Evid Based Complement Alternat Med eCAM, 423129","DOI":"10.1155\/2013\/423129"},{"issue":"6","key":"1387_CR17","doi-asserted-by":"publisher","first-page":"e0157193","DOI":"10.1371\/journal.pone.0157193","volume":"11","author":"A Haeckel","year":"2016","unstructured":"Haeckel A, Appler F, Ariza de Schellenberger A, Schellenberger E (2016) XTEN as Biological Alternative to PEGylation allows complete expression of a protease-activatable killin-based cytostatic. PLoS ONE 11(6):e0157193","journal-title":"PLoS ONE"},{"issue":"3","key":"1387_CR18","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1124\/jpet.119.257063","volume":"370","author":"AS Iyengar","year":"2019","unstructured":"Iyengar AS, Gupta S, Jawalekar S, Pande AH (2019) Protein chimerization: a new frontier for engineering protein therapeutics with improved pharmacokinetics. J Pharmacol Exp Ther 370(3):703\u2013714","journal-title":"J Pharmacol Exp Ther"},{"issue":"6","key":"1387_CR19","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1016\/j.copbio.2011.06.012","volume":"22","author":"RE Kontermann","year":"2011","unstructured":"Kontermann RE (2011) Strategies for extended serum half-life of protein therapeutics. Curr Opin Biotechnol 22(6):868\u2013876","journal-title":"Curr Opin Biotechnol"},{"key":"1387_CR20","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/j.jconrel.2019.02.016","volume":"301","author":"R Zaman","year":"2019","unstructured":"Zaman R, Islam RA, Ibnat N, Othman I, Zaini A, Lee CY, Chowdhury EH (2019) Current strategies in extending half-lives of therapeutic proteins. J Control Release 301:176\u2013189","journal-title":"J Control Release"},{"issue":"4","key":"1387_CR21","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1007\/s40259-015-0133-6","volume":"29","author":"WR Strohl","year":"2015","unstructured":"Strohl WR (2015) Fusion proteins for half-life extension of biologics as a strategy to make biobetters. BioDrugs 29(4):215\u2013239","journal-title":"BioDrugs"},{"issue":"40","key":"1387_CR22","doi-asserted-by":"publisher","first-page":"16095","DOI":"10.1073\/pnas.1208857109","volume":"109","author":"JT Sockolosky","year":"2012","unstructured":"Sockolosky JT, Tiffany MR, Szoka FC (2012) Engineering neonatal fc receptor-mediated recycling and transcytosis in recombinant proteins by short terminal peptide extensions. Proc Natl Acad Sci 109(40):16095\u201316100","journal-title":"Proc Natl Acad Sci"},{"issue":"38","key":"1387_CR23","doi-asserted-by":"publisher","first-page":"35035","DOI":"10.1074\/jbc.M205854200","volume":"277","author":"MS Dennis","year":"2002","unstructured":"Dennis MS, Zhang M, Meng YG, Kadkhodayan M, Kirchhofer D, Combs D, Damico LA (2002) Albumin binding as a general strategy for improving the pharmacokinetics of proteins. J Biol Chem 277(38):35035\u201335043","journal-title":"J Biol Chem"},{"key":"1387_CR24","doi-asserted-by":"crossref","unstructured":"Chen X, Zaro J, Shen WC (2013) Fusion protein linkers: effects on production, bioactivity, and pharmacokinetics. Fusion protein technologies for biopharmaceuticals: applications and challenges, 57\u201373","DOI":"10.1002\/9781118354599.ch4"},{"issue":"1","key":"1387_CR25","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1007\/s12010-016-2091-y","volume":"180","author":"P Bajaj","year":"2016","unstructured":"Bajaj P, Tripathy RK, Aggarwal G, Datusalia AK, Sharma SS, Pande AH (2016) Refolded recombinant human paraoxonase 1 variant exhibits prophylactic activity against organophosphate poisoning. Appl Biochem Biotechnol 180(1):165\u2013176","journal-title":"Appl Biochem Biotechnol"},{"key":"1387_CR26","unstructured":"Schabbauer G, Bluml S, Sahin-Heco E, Cheng P, Chen L (2017) Methods and compositions for modulating the immune system with arginase I. (U.S. Patent No. 9789169B2)"},{"issue":"41","key":"1387_CR27","doi-asserted-by":"publisher","first-page":"5216","DOI":"10.1038\/onc.2014.447","volume":"34","author":"J Kaur","year":"2015","unstructured":"Kaur J, Tikoo K (2015) Ets1 identified as a novel molecular target of RNA aptamer selected against metastatic cells for targeted delivery of nano-formulation. Oncogene 34(41):5216\u20135228","journal-title":"Oncogene"},{"issue":"1","key":"1387_CR28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-020-74847-7","volume":"10","author":"SK Surapaneni","year":"2020","unstructured":"Surapaneni SK, Bhat ZR, Tikoo K (2020) MicroRNA-941 regulates the proliferation of breast cancer cells by altering histone H3 ser 10 phosphorylation. Sci Rep 10(1):1\u201317","journal-title":"Sci Rep"},{"issue":"1\u20132","key":"1387_CR29","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/0022-1759(83)90303-4","volume":"65","author":"T Mosmann","year":"1983","unstructured":"Mosmann T (1983) Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 65(1\u20132):55\u201363","journal-title":"J Immunol Methods"},{"issue":"9","key":"1387_CR30","doi-asserted-by":"publisher","first-page":"5867","DOI":"10.1002\/jcp.29583","volume":"235","author":"M Karbalaei","year":"2020","unstructured":"Karbalaei M, Rezaee SA, Farsiani H (2020) Pichia pastoris: a highly successful expression system for optimal synthesis of heterologous proteins. J Cell Physiol 235(9):5867\u20135881","journal-title":"J Cell Physiol"},{"issue":"4","key":"1387_CR31","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1002\/yea.1208","volume":"22","author":"S Macauley-Patrick","year":"2005","unstructured":"Macauley-Patrick S, Fazenda ML, McNeil B, Harvey LM (2005) Heterologous protein production using the Pichia pastoris expression system. Yeast 22(4):249\u2013270","journal-title":"Yeast"},{"issue":"3","key":"1387_CR32","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1042\/bj2700697","volume":"270","author":"M Ikemoto","year":"1990","unstructured":"Ikemoto M, Tabata M, Miyake T, Kono T, Mori M, Totani M, Murachi T (1990) Expression of human liver arginase in Escherichia coli. Purification and properties of the product. Biochem J 270(3):697\u2013703","journal-title":"Biochem J"},{"key":"1387_CR33","unstructured":"Cheng NM (2012) Use of pegylated recombinant human arginase for treatment of leukemia. (U.S. Patent No. 20130295073A1)."},{"key":"1387_CR34","unstructured":"Cheng NM, Chen L (2015) Human arginase and pegylated human arginase and the use thereof. (U.S. Patent No. 9109218B2)."},{"key":"1387_CR35","doi-asserted-by":"crossref","unstructured":"Leung YC, Shum SW (2019) Composition and application of arginine-depleting agents for cancer, obesity, metabolic disorders, and related complications and comorbidities. (International publication No. WO 2019\/ 228510 A1).","DOI":"10.1007\/978-3-319-27316-7_3-2"},{"key":"1387_CR36","unstructured":"Cheng NM (2008) Pharmaceutical Composition and Method of treating Hepatitis with Arginases. (U.S. Patent No. 20080299638A1)"},{"issue":"1","key":"1387_CR37","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1756-8722-5-S1-A1","volume":"5","author":"EC Hsueh","year":"2012","unstructured":"Hsueh EC, Knebel SM, Lo WH, Leung YC, Cheng PN, Hsueh CT (2012) Deprivation of arginine by recombinant human arginase in prostate cancer cells. J Hematol Oncol 5(1):1\u20136","journal-title":"J Hematol Oncol"},{"issue":"12","key":"1387_CR38","doi-asserted-by":"publisher","first-page":"4234","DOI":"10.3390\/ijms21124234","volume":"21","author":"SF Chung","year":"2020","unstructured":"Chung SF, Kim CF, Kwok SY, Tam SY, Chen YW, Chong HC, Leung SL, So PK, Wong KY, Leung YC, Lo WH (2020) Mono-PEGylation of a thermostable arginine-depleting enzyme for the treatment of lung cancer. Int J Mol Sci 21(12):4234","journal-title":"Int J Mol Sci"},{"key":"1387_CR39","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.canlet.2020.12.041","volume":"502","author":"Y Zhang","year":"2021","unstructured":"Zhang Y, Chung SF, Tam SY, Leung YC, Guan X (2021) Arginine deprivation as a strategy for cancer therapy: an insight into drug design and drug combination. Cancer Lett 502:58\u201370","journal-title":"Cancer Lett"},{"issue":"7","key":"1387_CR40","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1517\/14712598.2016.1165661","volume":"16","author":"RE Kontermann","year":"2016","unstructured":"Kontermann RE (2016) Half-life extended biotherapeutics. Expert Opin Biol Ther 16(7):903\u2013915","journal-title":"Expert Opin Biol Ther"},{"key":"1387_CR41","unstructured":"DrugBank (2022): Powering health insights with structured drug data. https:\/\/www.drugbank.com, (accessed 15 June 2022)"},{"key":"1387_CR42","unstructured":"U.S National Libraray of Medicine, ClinicalTrials.gov: https:\/\/clinicaltrials.gov, 2022 (accessed 15 June 2022)"},{"issue":"49","key":"1387_CR43","doi-asserted-by":"publisher","first-page":"81880","DOI":"10.18632\/oncotarget.11980","volume":"7","author":"L Fang","year":"2016","unstructured":"Fang L, Jiang Y, Yang Y, Zheng Y, Zheng J, Jiang H, Zhang S, Lin L, Zheng J, Zhang S, Zhuang X (2016) Determining the optimal 5-FU therapeutic dosage in the treatment of colorectal cancer patients. Oncotarget 7(49):81880","journal-title":"Oncotarget"}],"container-title":["Investigational New Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-023-01387-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10637-023-01387-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-023-01387-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,18]],"date-time":"2023-12-18T05:39:38Z","timestamp":1702877978000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10637-023-01387-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,3]]},"references-count":43,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,10]]}},"alternative-id":["1387"],"URL":"https:\/\/doi.org\/10.1007\/s10637-023-01387-y","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-3118315\/v1","asserted-by":"object"}]},"ISSN":["0167-6997","1573-0646"],"issn-type":[{"value":"0167-6997","type":"print"},{"value":"1573-0646","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,3]]},"assertion":[{"value":"28 June 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 July 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 August 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"The mice with free access to food and water were maintained under standard environmental conditions in the Central Animal Facility of our Institute (NIPER, SAS Nagar) according to the institutional guidelines. All animals used in these studies were treated humanely and concerning the alleviation of suffering and pain. Our approved protocol is following the guidelines of the Committee for the Purpose of Control and Supervision of Experiment on Animals (CPCSEA), Ministry of Social Justice and Environment, Government of India. Rules of CPCSEA are laid down as per ILAR (Institute of Laboratory Animal Resources, USA) guidelines and prior permission was sought from the Institutional Animal Ethics Committee (IAEC No. IAEC\/21\/50) for conducting the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}]}}